

## Isconova's liquidity guarantee

As a consequence of that shareholders corresponding to 97.4% of the share capital have accepted the public tender offer by the US Nasdaq OMX-listed vaccine company Novavax, and that the extended acceptance period ends on August 20, the last day of the liquidity guarantee for the Isconova share will be August 15, 2013.

**For more information, please contact:**

Erik Bergman, CFO Isconova  
Phone: +46 18 16 17 29  
E-mail: [erik.bergman@isconova.com](mailto:erik.bergman@isconova.com)

**About Isconova**

Isconova AB is a Uppsala, Sweden, based research and development company, currently being acquired by Novavax, with a patented technology that enhances the efficacy and duration of vaccines. Isconova develops vaccines together with partners in veterinary and human markets, and since 2005, it has production and sales of vaccine adjuvants for the veterinary market. [www.isconova.com](http://www.isconova.com)